The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo (Pbo)-controlled phase III study of ombrabulin plus cisplatin in patients (pts) with advanced-stage soft-tissue sarcoma after failure of anthracycline and ifosfamide chemotherapies.
Zsuzsanna Papai
No relevant relationships to disclose
Anthony W. Tolcher
Consultant or Advisory Role - Abbott Laboratories (U); AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Astex Therapeutics (U); Bayer (U); BIND Biosciences (U); Bristol-Myers Squibb (U); Celator (U); Celgene (U); Clovis (U); Complete Genomics (U); Cougar Biotechnology (U); Curis (U); CytomX Therapeutics (U); Daiichi Sankyo (U); De Novo Pharmaceuticals (U); Dendreon (U); Dicerna (U); Eisai (U); EMD Serono (U); Endo Pharmaceuticals (U); Enzon (U); Everist Genomics (U); Exelixis (U); Five Prime Therapeutics (U); Galapagos (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Icon Clinical Research (U); Inovio Pharmaceuticals (U); Insert Therapeutics (U); Intellikine (U); Invivis (U); Janssen (U); Johnson & Johnson (U); Lilly (U); Merck (U); MethylGene (U); Micromet (U); NantWorks (U); Nektar (U); Neumedicines (U); Novartis (U); Oncogenex (U); OncoMed (U); Onyx (U); Otsuka (U); Pfizer (U); PPD Development LP (U); Precision Health Holdings (U); ProNAi (U); Regeneron (U); Sanofi (U); Spectrum Pharmaceuticals (U); Sunovion (U); Symphogen (U); Triphase Accelerator Corp (U); Vaccinex (U); Veeda Oncology (U); Zyngenia (U)
Research Funding - Sanofi
Antoine Italiano
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Didier Cupissol
No relevant relationships to disclose
Antonio Lopez-Pousa
No relevant relationships to disclose
Sant P. Chawla
Consultant or Advisory Role - CytRx Corporation; Merck; PharmaMar; Sanofi
Research Funding - CytRx Corporation; Merck; PharmaMar; Sanofi
Emmanuelle Bompas
No relevant relationships to disclose
Nicolas Penel
Research Funding - Bayer; Janssen; Novartis; PharmaMar; Roche
Nicolas Isambert
No relevant relationships to disclose
Arthur P. Staddon
No relevant relationships to disclose
Antoine Thyss
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Fabio A. Franke
No relevant relationships to disclose
Patrick Cohen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Solenn Le-Guennec
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
George D. Demetri
Consultant or Advisory Role - ARIAD; Blueprint Medicines (U); Champions Biotechnology; Foundation Medicine; G1 Therapeutics; GlaxoSmithKline; Johnson & Johnson; Kolltan Pharmaceuticals (U); Merck; Merrimack; N-of-One (U); Novartis; Pfizer; Sanofi ; ZIOPHARM Oncology
Stock Ownership - Blueprint Medicines; Champions Biotechnology; G1 Therapeutics; Kolltan Pharmaceuticals; N-of-One
Research Funding - GlaxoSmithKline; Johnson & Johnson; Merck; Novartis; Pfizer; Sanofi
Expert Testimony - GlaxoSmithKline (U); Johnson & Johnson (U); Merck (U)
Jean-Yves Blay
Consultant or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; MSD; Novartis; Pfizer; PharmaMar; Roche
Expert Testimony - MSD (U)